News | June 29, 2022
Glenmark Pharmaceuticals expand its OTC portfolio
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The company has received approval from DCGI to begin patient enrolment and dosing in the country
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health
Subscribe To Our Newsletter & Stay Updated
